Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上海復星醫藥（集團）股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (a joint stock limited company incorporated in the People’s Republic of China with limited liability) (Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following sets out the “Announcement in Relation to the Progress of Drug Clinical Trial by a Subsidiary” published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “Company”) on the website of the , for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Chen Qiyu Chairman

Shanghai, the People’s Republic of China

10 September 2020

As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors of the Company are Mr. Xu Xiaoliang, Mr. Gong Ping and Mr. Pan Donghui; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

* for identification purposes only Stock code: 600196 Stock abbreviation: Announcement No.: Lin 2020-140 Bond code: 136236 Bond abbreviation:16 Fosun 01 Bond code: 143020 Bond abbreviation:17 Fosun 01 Bond code: 143422 Bond abbreviation:18 Fosun 01 Bond code: 155067 Bond abbreviation:18 Fosun 02 Bond code: 155068 Bond abbreviation:18 Fosun 03

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Announcement in Relation to the Progress of Drug Clinical Trial by a Subsidiary

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and severally and jointly accept full responsibility for the truthfulness, accuracy and completeness of this announcement.

I. Overview

Recently, Avanc Pharmaceutical Co., Ltd.* ( 錦州奧鴻藥業有限責任公司) (“Avanc Pharma”), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥（集團）股份有限公司) (the “Company”), commenced phase II clinical trial on FCN-437c (the “Investigational New Drug”) for the indications of ER+ and HER2- advanced breast cancer in the PRC (excluding Hong Kong and Special Administrative Regions and Taiwan Region, the same below).

II. Research Progress of the Investigational New Drug

The Investigational New Drug is a CDK4/6 inhibitor, a small molecule innovative drug independently developed by the Group (i.e. the Company and its subsidiaries/units, the same below), and is mainly used for the treatment of advanced/metastatic solid tumor (including ER+ and HER2- advanced breast cancer). Fochon Pharmaceuticals, Ltd.* ( 重慶復 創醫藥研究有限公司), a subsidiary of the Company, started the pre-clinical research and granted Avanc Pharma the exclusive right to develop and commercialize the Investigational New Drug in the PRC. As at the date of this announcement, the Investigational New Drug is under phase I and phase II clinical trial in PRC and is under phase I clinical trial in US.

As at the date of this announcement, the CDK4/6 inhibitor launched in the PRC is palbociclib capsule manufactured by Inc. According to the latest data from IQVIA CHPA (provided by IQVIA, a global leading provider of professional information and strategic consulting services for the pharmaceutical and health industry; IQVIA CHPA data represents the sales market of drugs for hospital with over 100 beds in the PRC. Due to the differences in the sales channels of drugs, the actual sales may vary from the IQVIA CHPA data on difference degrees), the sales of palbociclib capsule in the PRC amounted to approximately RMB63.55 million in 2019.

As at August 2020, the cumulative research and development (“R&D”) investment of the Group in the Investigational New Drug was in the amount of approximately RMB95.68 million (unaudited) at this stage.

III. Risk Reminder

There are certain risks in the R&D of new drugs based on the experience. For example, clinical trials may be terminated due to issues such as safety and/or efficacy.

As required by the relevant laws and regulations in the PRC, the Investigational New Drug is subject to a series of clinical studies and the approval from the national drug evaluation authority in the PRC before it can be marketed.

The R&D and marketing of new drugs is a long-term task involving various uncertainties. Investors should be aware of the investment risks.

Announcement is hereby given.

The board of directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 10 September 2020

* for identification only